Mass spectrometry (MS) can detect trace components and generate highly specific molecular information, but accurate mass alone rarely provides a complete structural assignment. Ionization behavior, adduct formation, fragmentation, matrix effects, isomers, and chromatographic separation all influence the conclusion. Triclinic Labs applies liquid chromatography/mass spectrometry (LC/MS), gas chromatography/mass spectrometry (GC/MS), high-resolution mass spectrometry (HRMS), tandem mass spectrometry (MS/MS), inductively coupled plasma mass spectrometry (ICP-MS), and complementary nuclear magnetic resonance (NMR) spectroscopy, chromatography, spectroscopy, and crystallography to identify impurities, degradants, contaminants, extractables, leachables, and unknown materials and to support defensible structure elucidation. Our scientists focus on building an evidence-based identification that can withstand technical, quality, and regulatory review.
The content of this page has been scientifically reviewed by David Bugay, Ph.D., CSO at Triclinic Labs · Updated 8/1/2026
Mass spectrometry measures mass-to-charge ratios of ions. Coupled to liquid chromatography (LC) or gas chromatography (GC), it separates mixture components before detection; HRMS adds high-resolution accurate-mass data; MS/MS fragmentation supports structural hypotheses; ICP-MS supports trace elemental analysis.
Use MS for impurity identification, degradation products, extractables/leachables, metabolite or small-molecule characterization, polymer/additive work, trace-level detection, elemental impurities, and structure-elucidation support.
Ionization bias, matrix effects, adducts, in-source fragmentation, isomer ambiguity, poor chromatographic separation, and lack of authentic standards can limit certainty. MS often needs NMR, microcrystal electron diffraction (MicroED), chromatography, infrared (IR)/Raman spectroscopy, or synthesis confirmation.
MS can be highly sensitive, but sample amount depends on concentration, ionization efficiency, matrix cleanup, replicate needs, and whether isolation is required. Trace analysis and structure identification should be scoped before assuming enough material exists.
Complementary techniques include nuclear magnetic resonance (NMR), chromatography with non-MS detectors, Fourier-transform infrared (FTIR) and Raman spectroscopy, MicroED, single-crystal X-ray diffraction (SCXRD), inductively coupled plasma optical emission spectroscopy (ICP-OES), and X-ray fluorescence (XRF). They add connectivity, phase, crystal-structure, functional-group, or elemental evidence to mass and fragmentation data.
FDA cares about impurity identity, detection/quantitation limits, mass accuracy, specificity, validated sample prep, reference standards where needed, and whether the method supports the proposed control strategy under International Council for Harmonisation (ICH) Q2(R2)/Q14 and, for elements, ICH Q3D.
Common mistakes include reporting exact mass as a complete structure, ignoring adducts/isotopes, failing to prove coelution was resolved, over-assigning fragments, and not confirming clinically or toxicologically relevant impurities with orthogonal data.
Triclinic uses mass spectrometry to investigate unknowns, impurities, degradants, contaminants, extractables, leachables, and reaction or process-related components in real materials. Practical applications include assigning likely molecular formulas, comparing suspect peaks across lots or conditions, tracing degradation pathways, supporting impurity control strategies, and pairing accurate-mass data with orthogonal chemistry to reach defensible identifications.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) | Voyager DE Pro MALDI | High-mass-range MALDI-TOF for polymers, lipids, oligosaccharides, phosphopeptides, proteins, and small molecules; molecular-weight and distribution support up to high mass ranges. |
| Triple quadrupole LC/MS/MS | Agilent 6460 Triple Quad LC/MS/MS | Trace-level detection and quantitative LC/MS/MS workflows for impurities, degradants, environmental, pharmaceutical, and clinical-style assays. |
| High-resolution accurate-mass LC/MS | Thermo Fisher Scientific Orbitrap Exploris 120 MS with Vanquish LC; quadrupole/ion-routing multipole/Orbitrap architecture; higher-energy collisional dissociation (HCD) and in-source fragmentation | High-resolution accurate-mass analysis with resolution up to 120,000 full width at half maximum (FWHM), ultra-high-performance liquid chromatography/liquid chromatography (UHPLC/LC) workflows, unknown ID, formula constraints, and impurity/degradant characterization. |
| GC/MS | Thermo Fisher Scientific Thermo 8000 GC/MS; electron-impact ionization; DB-5 column and thermal-gradient operation | Volatile and semi-volatile component identification, residual-solvent support, and electron ionization (EI) fragmentation/library-searchable spectra. |
| ICP-MS and HPLC-ICP-MS | Thermo Fisher Scientific iCAP RQ single-quadrupole ICP-MS; high-performance liquid chromatography coupling for speciation workflows | Total elemental and isotopic analysis, trace-metal quantitation, and chromatographic separation followed by element-selective detection for elemental speciation and differentiation of chemical forms. |
This example organizes common mass-spectrometry uses into a scoping table. Mass spectrometry can provide molecular, fragment, and elemental information with high sensitivity, but the right technique depends on the analyte, matrix, and decision. The table below shows how the same broad platform family can support different characterization questions.
| Material class | Mass-spectrometry use example |
|---|---|
| Small molecules, pharmaceuticals, and organic compounds | Molecular structure, purity, composition, degradation products, drugs, pesticides, pollutants, and synthetic chemicals. |
| Polymers and coatings | Molecular-weight distribution, polymer composition, cross-linking, degradation, additives, plasticizers, or impurities. |
| Biomolecules | Protein, peptide, lipid, nucleic-acid, and carbohydrate identification or quantitation using approaches such as MALDI-MS or LC-MS/MS. |
| Natural products | Molecular weights and structures of unknown compounds in complex natural-product mixtures, supplements, or plant extracts. |
| Metals and inorganic materials | Elemental and isotopic analysis using ICP-MS for metal alloys, nanomaterials, environmental samples, or geological materials. |
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: Gary C. George III, Jason Vanlerberghe, and Stephan X.M. Boerrigter
Publication date: Q1 2026
Abstract: A hybrid workflow uses HRMS to provide accurate-mass and formula constraints and MicroED to provide crystallographic structure evidence for trace impurities that may be difficult to isolate in amounts needed for traditional methods.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Author: International Council for Harmonisation
Publication date: 2022
Abstract: ICH Q3D(R2) provides the risk-management framework for assessing and controlling elemental impurities in drug products. It is the regulatory anchor for elemental-impurity testing, method selection, and justification of ICP-MS, XRF, or other elemental-analysis strategies.
Characterizes density, flow, particle size, moisture response, surface behavior, and morphology to explain powder handling and manufacturing performance.
View techniqueIdentifies crystalline phases and solid forms, measures crystallinity, and tracks polymorph, hydrate, solvate, or salt changes.
View techniqueDetermines molecular and crystal structures from sub-micron crystals when conventional single-crystal analysis is not practical.
View techniqueMeasures melting, glass transitions, crystallization, solvent loss, and decomposition to connect thermal behavior with stability and processing.
View techniqueQuantifies water, distinguishes bound from surface moisture, and evaluates sorption, desorption, hydrate formation, and humidity-driven change.
View techniqueProvides rapid molecular-identification, functional-group, solid-form, mixture, and spatial-distribution evidence using Raman, FTIR, IR imaging, and UV/Vis.
View technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
